NBCNBC News·1hHealth
score+0.70
Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
Original
Personalized mRNA vaccine for melanoma cut risk of cancer’s return in late-stage trial
“The headline highlights a significant 42% risk reduction in a late-stage trial, conveying strong clinical progress and optimism.”